Gossamer Bio Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in the areas of immunology, inflammation, and oncology. The company is based in San Diego, California, and was founded in 2018 by former executives of Receptos, a biotech company acquired by Celgene in 2015. The founding team has a track record of developing and commercializing successful drugs.
Gossamer Bio's product pipeline includes multiple drug candidates in various stages of development. The company's lead candidate, GB001, is a Phase 3-ready drug being developed for the treatment of eosinophilic asthma, a type of asthma that is associated with high levels of white blood cells known as eosinophils. GB001 is an oral small molecule inhibitor of a protein called prostaglandin D2 receptor 2 (DP2), which is believed to play a role in eosinophilic inflammation. The company is also developing GB002, an oral small molecule inhibitor of the immunomodulatory protein S1P, for the treatment of inflammatory bowel disease.
Gossamer Bio went public in February 2019, with an initial public offering (IPO) that raised $276 million. The IPO was oversubscribed, and the company's stock price surged on its first day of trading. The proceeds from the IPO are being used to fund the development of GB001 and other drug candidates in the company's pipeline. Since going public, Gossamer Bio's stock price has fluctuated, reflecting the risks and uncertainties inherent in the biopharmaceutical industry.
The company has entered into collaborations with other pharmaceutical companies to develop and commercialize its drug candidates. In 2019, Gossamer Bio entered into a collaboration agreement with Japan-based pharmaceutical company Asahi Kasei Pharma Corporation to develop and commercialize GB001 in Japan. The company has also partnered with Chinese biopharmaceutical company Zai Lab to develop and commercialize its drugs in China.
In summary, Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing therapeutics in the areas of immunology, inflammation, and oncology. The company's lead drug candidate, GB001, is being developed for the treatment of eosinophilic asthma, and the company is also developing other drug candidates for inflammatory bowel disease and oncology. Gossamer Bio went public in 2019 and has since entered into collaborations with other pharmaceutical companies. The company is led by a management team with extensive experience in biotech and finance.